New chairman in Likvor and new distributor in Germany

The medtech company Likvor AB strengthens its competences with a new chairman of the board, Stefan Sallerfors. Sallerfors has a background as doctor and specialist in medical radiology and has been CEO for GE Medical System Sverige AB and Helsingborg hospital. In November Likvor continues the expansion on the European market with a new distribution agreement for the German market. The unique Likvor CELDA® System is therefore available in Germany, Austria and Switzerland through the new distributor, Neuromed. The system helps to restore normal life back to millions of dementia patients with hydrocephalus diagnosis.

Stefan Sallerfors takes over as chairman of the board in Likvor after Jan Olsson, who has had the position since the start of the company. Sallerfors has a background from the health care and medtech industry and strengthens Likvor in the expansion on the European market. Sallerfors is involved as chairman in several companies and works as a consultant at Solving Efeso, a top management consultancy firm with offices worldwide.

Likvor's new distributor Neuromed is a spin out from Micromed Medizin Electronik with the same owner, Andreas and Richard Brandmeier. Neuromed's primary focus is on sales, marketing and service of products in the area of neuroscience and neurology. The new distributor will take the unique Likvor CELDA® System to the German speaking countries.

Earlier this fall Likvor AB signed a distribution agreement for the UK market with Seren Medical Ltd. Seren Medical is a company specializing in sales, marketing, service and support of state-of-the-art medical equipment. Please read more about Seren Medical Ltd. at

The Likvor CELDA® System is being successfully used in leading neurological clinics in Sweden, Denmark, Finland and from October 2011 also in United Kingdom.

Statistics show that about one in 10 dementia patients suffer from an undiagnosed or misdiagnosed condition known as treatable or reversible dementia (NPH - normal pressure hydrocephalus). The symptoms of NPH commonly include difficulty in walking, urinary incontinence, and mild dementia. The condition generally manifests in over 55 year-olds. In contrast to dementia, NPH can be treated by means of a simple operation to give sufferers a completely new lease on life. Studies indicate that approximately 1.4 million patients in Europe, USA and Japan suffer from NPH.

Together with the fact that the Likvor CELDA® System is used for diagnose/exclude NPH patients from other dementia diseases as Alzheimer or Parkinson's the Likvor CELDA® System is a very useful tool for investigating shunt function. It can be used for diagnosis of existing shunts. By using the Likvor CELDA® System hospitals can make huge savings, in costs as they reduce the number of shunt reoperations and in human suffering.

Likvor is an Umeå based medical device company which has developed a system to be used in neurological investigations. The Likvor CELDA® System is the result of over 30 years of research at Umeå University and Umeå University Hospital assessing cerebrospinal fluid (CSF) dynamics. Likvor is marketing the Likvor CELDA® System and CELDA® Tools. Likvor continues to develop new methods and devices in the area of CSF dynamics, together with the researchers at Umeå University and Umeå University Hospital.